StoneX Group’s iShares US Pharmaceuticals ETF IHE Stock Holding History

StoneX Group’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,290	Closed	-$234K	–	375
2020 Q3	$234K	Buy	4,290 +39	+0.9%	+$2.1K	0.08%	269
2020 Q2	$218K	Buy	+4,251	New	+$214K	0.08%	256
2020 Q1	–	Sell	-4,080	Closed	-$218K	–	281
2019 Q4	$218K	Buy	+4,080	New	+$201K	0.09%	274

Other funds holding IHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

StoneX Group's IHE Position: Q4 2020 in Review

StoneX Group sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2020, closing a stake of 4,290 shares — an estimated $234K sold.

StoneX Group first reported a position in IHE in Q4 2019 and held it in 3 quarters. The position peaked at $234K in Q3 2020. 99 funds tracked by Wall St. Rank hold IHE as of Q4 2020.

StoneX Group reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2020 after selling out during the quarter.
StoneX Group sold 4,290 iShares US Pharmaceuticals ETF shares in Q4 2020, an estimated $234K.
StoneX Group first reported a position in iShares US Pharmaceuticals ETF in Q4 2019 and held it in 3 quarters.
StoneX Group's iShares US Pharmaceuticals ETF position peaked at $234K in Q3 2020.
99 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2020.

Based on StoneX Group's 13F filing for Q4 2020, filed 3 Feb 2021.